Overview

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for Treatment of Plaque Psoriasis in Adults

Status:
Withdrawn
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
This trial will be a double-blind, single-center, randomized, placebo controlled study to evaluate the safety, tolerability, and efficacy of SAN021 study drug when administered for up to 42 days to adults between the ages of 18 to 65 years who have a clinical diagnosis of mild-to-moderate plaque psoriasis.
Phase:
Phase 2
Details
Lead Sponsor:
Santalis Pharmaceuticals, Inc.
Collaborators:
ClinDatrix, Inc.
Fremantle Dermatology